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AbsTrACT
Objective To evaluate the cost- effectiveness of two 
rates of enteral feed advancement (18 vs 30 mL/kg/day) 
in very preterm and very low birth weight infants.
Design Within- trial economic evaluation alongside 
a multicentre, two- arm parallel group, randomised 
controlled trial (Speed of Increasing milk Feeds Trial).
setting 55 UK neonatal units from May 2013 to June 
2015.
Patients Infants born <32 weeks’ gestation or <1500 
g, receiving less than 30 mL/kg/day of milk at trial 
enrolment. Infants with a known severe congenital 
anomaly, no realistic chance of survival, or unlikely to be 
traceable for follow- up, were ineligible.
Interventions When clinicians were ready to start 
advancing feed volumes, infants were randomised to 
receive daily increments in feed volume of 30 mL/kg 
(intervention) or 18 mL/kg (control).
Main outcome measure Cost per additional survivor 
without moderate to severe neurodevelopmental 
disability at 24 months of age corrected for prematurity.
results Average costs per infant were slightly higher 
for faster feeds compared with slower feeds (mean 
difference £267, 95% CI −6928 to 8117). Fewer infants 
achieved the principal outcome of survival without 
moderate to severe neurodevelopmental disability at 24 
months in the faster feeds arm (802/1224 vs 848/1246). 
The stochastic cost- effectiveness analysis showed a 
likelihood of worse outcomes for faster feeds compared 
with slower feeds.
Conclusions The stochastic cost- effectiveness analysis 
shows faster feeds are broadly equivalent on cost 
grounds. However, in terms of outcomes at 24 months 
age (corrected for prematurity), faster feeds are harmful. 
Faster feeds should not be recommended on either cost 
or effectiveness grounds to achieve the primary outcome.
InTrODuCTIOn
The total cost of preterm birth to the public sector 
is nearly £3 billion over childhood, of which 34% is 
attributable to very preterm birth before 32 weeks 
of gestation.1 Costs arise from increased healthcare 
resource utilisation such as hospital inpatient and 
outpatient care, community care and medications.2 
There are also considerable societal costs associ-
ated with preterm birth- related morbidities, such 
as productivity loss resulting from time taken off 
work by parents and carers and additional expen-
diture on home adjustments, special equipment 
and travel.2 3 There is uncertainty regarding enteral 
feeding practices of very preterm and very low birth 
weight (VLBW; <1500 g) infants. Increasing milk 
volumes slowly is associated with increased risk 
of late onset sepsis (LOS),4–6 while faster increases 
may increase the likelihood of necrotising entero-
colitis (NEC).7 In very preterm or VLBW infants, 
LOS and NEC are important causes of long- term 
neurodevelopmental disability.7 8 Children with 
neurodevelopmental disabilities require a range of 
services beyond simply healthcare, such as social 
services, special educational support and rehabili-
tation9 and costs accrue throughout the individu-
al’s lifespan. The Speed of Increasing milk Feeds 
Trial (SIFT) aimed to address uncertainty in enteral 
feeding practices by comparing two rates of enteral 
feed advancement (18 vs 30 mL/kg/day) in very 
preterm and VLBW infants.7 This paper presents 
the economic evaluation undertaken alongside 
SIFT.
MeThODs
Details of the trial have been published elsewhere.7 
Briefly, 2804 babies were recruited into the trial, 
of which 1400 were randomised to faster feeds 
What is already known on this topic?
 ► Economic evidence regarding enteral feeding 
regimes is scarce.
 ► Previous randomised controlled trial (RCT) 
evidence was based on short- term outcome 
data.
 ► The Speed of Increasing milk Feeds Trial was the 
largest enteral feeding regime trial and the first 
to report neurodevelopmental outcomes at 2 
years of age.
What this study adds?
 ► This is the first economic evaluation of enteral 
feeding practices alongside a RCT.
 ► Increasing milk feed volumes at a faster rate in 
very preterm or very low birth weight infants is 
not a cost- effective strategy.
 ► The costs and consequences of faster feeds in 
the long term are likely too high to recommend 
this as routine clinical practice.
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Table 1 Unit costs of resource items (2017–2018 prices)
resource use items unit cost (£)* source
Intervention
  Cost per day on parenteral nutrition 45 Walter et al28
Intensive care
  Cost per day in intensive care
  (differentiated by level of care 
required)
NHS Reference Costs29
  Level 1—Intensive Care 1295
  Level 2—High Dependency Care 1032
  Level 3—Special Care 510
Initial hospital stay
  Cost per pulmonary haemorrhage 1485 NHS Reference Costs29
  Cost per IVH by severity:
   Grade 1 IVH/Germinal matrix 
haemorrhage
862 NHS Reference Costs29
   Grade 2 IVH 1472 NHS Reference Costs29
   Grade 3/4 IVH 1519 NHS Reference Costs29
  Course of shunts for hydrocephalus 2608 NHS Reference Costs29
  Bronchopulmonary dysplasia 5954 NHS Reference Costs29
  Periventricular leukomalacia 1341 NHS Reference Costs29
  Retinopathy treated medically or 
surgically
1603 NHS Reference Costs29
  PDA treated with NSAID 1152 BNFC30
  Surgeries due to gut signs 6629 NHS Reference Costs29
  Cost of antibiotic medication per 
day
3.00 BNFC30
  Cost of antifungal treatment per day 1.06 BNFC30
  Cost per mL of Preterm milk formula 0.02 Ganapathy et al31
  Cost per packet of breast milk 
fortifier
0.93 Ganapathy et al31
  Cost per litre of donor breast milk 335 Renfrew et al32
  Cost per 200 mL of term formula 
milk
2.00 Renfrew et al32
Resource use during 2- year follow- up
  Cost per out- patient day 199 NHS Reference Costs29
  Cost per in- patient day 635 NHS Reference Costs29
  Cost per operation 2247 NHS Reference Costs29
  Cost per GP visit 33 Curtis and Burns10
  Cost per Health Visitor visit 75 Curtis and Burns10
  Cost per Community Nurse visit 36 Curtis and Burns10
  Cost per Home Visitor/Volunteer visit 19 Curtis and Burns10
  Cost per Community Paediatrician 
visit
407 NHS Reference Costs29
  Cost per Physiotherapist visit 95 NHS Reference Costs29
  Cost per Social Worker visit 39 Curtis and Burns10
  Cost per Speech and language 
therapist visit
95 NHS Reference Costs29
  Cost per Dietician visit 85 NHS Reference Costs29
  Cost per Other health professional 
visit
135 NHS Reference Costs29
*Inflated to 2017–2018 costs using the UK hospital and community health services 
pay and prices index. Costs were assigned using a macrocosting (top- down) 
approach.20
GP, general practitioner; IVH, intraventricular haemorrhage (intracranial 
abnormality); NSAID, non steroidal anti- inflammatory drugs; PDA, patent ductus 
arteriosus.
and 1404 were randomised to slower feeds. Outcomes were 
assessed until discharge home from neonatal units and again at 
age 24 months, corrected for prematurity (see online supple-
mentary material figure S1). Resource use data were collected 
prospectively from centres participating in the trial. All centres 
completed a total of eight different data collection forms that 
included specific items measuring healthcare use. Where serious 
adverse events were reported, the associated resource use was 
collected on an additional form by the relevant participating 
centres. Health service use for the first 2 years of life was also 
measured through a parent questionnaire, which included 
healthcare- related resource use items such as use of primary care 
services and hospital readmissions.7
COsTs
A National Health Service and Personal Social Services perspec-
tive was adopted; thus, only the direct costs to the health service 
provider during the trial’s duration were considered.
Table 1 presents the relevant items of resource use, their asso-
ciated unit costs and the source from which these costs were 
obtained. All costs were expressed in pounds sterling (GBP) 
and in 2017–2018 prices. Costs were inflated where necessary, 
using the hospital and community health services index.10 More 
detail on resource use and disaggregated costs is presented in the 
online supplementary tables S1 and S2.
eCOnOMIC AnAlysIs
A preliminary cost- consequence analysis was conducted to 
compare the disaggregated costs and outcomes for both feeding 
increments.11 Mean costs per infant were estimated for each arm 
and the mean cost differences between the two feeding alloca-
tions were calculated. A bootstrapping approach with replace-
ment was undertaken to calculate CIs around the mean costs.12
The primary base case economic analysis took the form of 
a cost- effectiveness analysis, a method for assessing the gains 
in health relative to the costs of the different health interven-
tions.13 Costs and clinical outcomes associated with each feeding 
allocation were combined by calculating incremental cost- 
effectiveness ratios (ICERs). Cost data were discounted at 3.5% 
but discounting is not applied to outcomes in natural units. Cost- 
effectiveness was based on the principal outcome of additional 
cost per survivor without disability at 24 months corrected age.
sTOChAsTIC COsT-effeCTIveness AnAlysIs
A stochastic cost- effectiveness analysis (PSA) was conducted on 
the base- case results. The approach taken in the PSA is that all 
important variables relating to costs and clinical outcomes are 
given a distribution that describes the uncertainty surrounding 
the mean. The distributions are simulated 5000 times. Each 
time, random numbers are drawn from the appropriate distribu-
tions. After each simulation, the incremental costs and effects are 
plotted in a cost- effectiveness plane which comprises four quad-
rants: north- east (NE), north- west (NW), south- east (SE) and 
south- west (SW). The scatterplot that is produced represents the 
simulations. If dots from the scatterplot are in the NE quadrant, 
this indicates that the intervention is more costly and more effec-
tive compared with the comparator (slower feeds). Dots in the 
NW quadrant indicate that the intervention is more costly and 
less effective than the comparator. Based on these simulations, 
the probability that the intervention would be cost- effective is 
presented. This is the standard approach for health economics 
following accepted guidelines (CHEERS)14 and is a presentation 
of results of cost- effectiveness studies which would be required 
by decision- makers such as NICE.15
Results were also presented using cost- effectiveness accept-
ability curves (CEACs) to reflect sampling variation and 
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Table 2 Mean total costs (£s sterling, 2016–2017 prices)
Cost category
faster increments (n=1224) slower increments (n=1246)
Total cost Mean sD Total cost Mean sD
bootstrap mean 
difference (95% CI)
Costs of initial hospital care 124 386 552 101 623* 80 759 126 923 790 101 865 80 498 −242 (−6307 to 6251)
Costs from initial discharge from hospital up to 24 
months corrected age
10 151 856 8294 49 585 9 698 864 7784 38 473 510 (−2864 to 4508)
Total costs of health service use after initial 
discharge from hospital and up to 24 months 
corrected age†
134 538 408 109 917 98 040 136 623 900 109 650 94 788 267 (−6928 to 8117)
*Mean total costs are calculated as total cost for this category divided by the sample size of the arm (eg, 124 386 552/1224 for costs of initial hospital care in the faster feeding 
arm).
†Total costs are the sum of costs of initial hospital care and costs from discharge up to 24 months corrected age.
uncertainties in the cost- effectiveness value where appropriate. 
A CEAC shows the probability that an intervention (eg, faster 
feed increments) is cost- effective compared with the alternative 
(eg, slower feed increments), given the observed data, for a range 
of maximum monetary values (thresholds) that decision- makers 
might be willing to pay for a particular unit change in outcome.16 
We examined cost- effectiveness across a range of monetary will-
ingness to pay thresholds, 0–£40 000 per additional survivor 
without disability at 24 months corrected age. To account for 
missing resource use data where follow- up data were not avail-
able, multiple imputation was performed following published 
and widely implemented methodology.17 18 We used the multiple 
imputation technique of predictive mean matching to impute 
the missing values for total costs at 2 years. The imputation 
model was based on treatment group, and used M=20 imputed 
datasets.
resulTs
Participants
A total of 2804 infants were recruited, 1400 of which were 
randomised to faster feeds and 1404 to slower feeds. The propor-
tions of infants withdrawn from the trial or lost to follow- up are 
presented in online supplementary figure S1. The data on the 
primary outcome at 24 months were available in 1224 (87.4%) 
of the faster group and 1246 (88.7%) of the slower group. The 
primary base case analysis comprised of only those infants for 
whom there was complete outcome data.
resource use and costs
The number of parents who fully completed the resource use 
questionnaire was 842/1224 (68.8%) and 873/1246 (70%) in the 
fast and slow feeding increment arms of the trial, respectively. 
Average volumes of resource use and costs per infant during 
initial hospital stay and postdischarge up to 2 years corrected 
age are detailed in online supplementary tables S1 and S2.
There was very little variation in resource use during initial 
hospital stay and postdischarge between groups. Postdischarge 
health service costs were generally higher for the faster incre-
ment, particularly for primary care services such as general prac-
titioner, health visitor and community nurse visits.
The mean costs for each group are presented in table 2. The 
cost for faster feeds was, on average, an estimated £242 less per 
infant (95% CI −6307 to 6251) than slower feeds during infants’ 
initial hospital stay. However, during the 2 year follow- up, the 
faster increment group was more costly, on average, by approx-
imately £510 (95% CI −2864 to 4508) per infant. In terms of 
costs up to 24 months, faster feeds were slightly more costly by, 
on average, £267 (95% CI 6928 to 8117) per infant.
Cost-consequence analysis
In terms of overall costs, the average cost per infant for faster 
feeds was slightly more costly than slower feeds (mean difference 
£267, 95% CI −6928 to 8117).
Although there were fewer deaths in the faster feed group, 
for the primary outcome of survival without moderate or severe 
neurodevelopmental disability at 24 months corrected age, the 
intervention (faster feeds) was less effective than the compar-
ator (slower feeds). Increasing milk feeds at a faster rate was 
associated with 46 (2.6%) more infants with moderate to severe 
disability compared with the slower feed group (mean differ-
ence: 0.96, 95% CI 0.92 to 1.01).
The breakdown of costs shows that faster feeds compared with 
slower feeds is slightly less costly, on average, during infants’ 
initial hospital stay, but in the postdischarge period up to 24 
months, the 2- year follow- up data show that costs are greater 
in those allocated faster increments, on average. This resulted 
in a slightly higher mean total cost per infant in the intervention 
arm (faster feeds). This is due to greater resource use associated 
with faster increments, in terms of hospital inpatient stays and 
primary care visits in the postdischarge period (online supple-
mentary table S1 and S2).
Cost-effectiveness analysis
Faster feeds are shown to cost more per infant on average and 
are also less effective in achieving the primary outcome; thus, 
they are dominated by the comparator (slower feeds) (see 
table 2, table 3, figure 1). There is therefore no ICER to present 
in this circumstance.
stochastic cost-effectiveness analysis
The cost- effectiveness plane for the base- case analysis is 
presented in figure 1. The majority of the scatterplots (depicting 
paired incremental costs and outcomes) are in the NW and SW 
quadrants. Scatterplots falling in the NW quadrant represent 
higher cost and worse outcome than the comparator, while 
scatterplots in the SW quadrant represent worse outcome and 
lower costs. Thus, figure 1 suggests that faster feed increments 
are a less effective intervention. However, it is uncertain whether 
faster feeds are likely to be more costly (NW) or less costly (SW) 
relative to slower feed increments. The CEAC (figure 2) shows 
the probability of faster feeds being cost- effective at various 
values of decision- makers’ willingness- to- pay per additional 
survivor without moderate to severe disability at 24 months of 
age (corrected for prematurity). The CEAC (figure 2) suggests 
that the probability of the intervention being cost- effective is 
less than 50% for all willingness to pay values. In addition, the 
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Table 3 Cost- consequence and cost- effectiveness analyses
Costs/Consequences
faster increments
(n=1224)
slower increments
(n=1246)
Total costs of health service use for 
2 years
134 538 408 £136 623 900
Costs of initial hospital care £124 386 552 £126 923 790
Costs from initial discharge from 
hospital up to 24 months corrected age
£10 151 856 £9 698 864
Survival at hospital discharge 1332/1394
(95.57%)
1337/1399
(95.23%)
Death before discharge home 60/1392
(4.3%)
65/1393
(4.7%)
Survival without moderate or severe 
neurodevelopmental disability at 24 
months
802/1224
(65.5%)
848/1246
(68.1%)
Survival (at 24 months, corrected age) 1326/1394
(95.1%)
1322/1399
(94.5%)
Moderate to severe 
neurodevelopmental disability
473/1394
(33.9%)
405/1399
(28.9%)
Neonatal late onset invasive infection 
(LOII)
414/1389
(29.8%)
434/1397
(31.1%)
NEC 70/1394
(5.0%)
78/1399
(5.6%)
Disability was defined as moderate/severe in any of the following categories any 
of: moderate/severe visual impairment, moderate/severe hearing impairment, 
moderate/severe gross motor impairment or moderate/severe cognitive impairment.
NEC, necrotising enterocolitis.
figure 1 Cost- effectiveness plane (fast vs slow feeds). NE, north- east; 
NW, north- west; SE, south- east; SW, south- west.
figure 2 Cost- effectiveness acceptability curve (fast vs slow feeds). 
SIFT, Speed of Increasing milk Feeds Trial.
probability of cost- effectiveness decreases as the willingness to 
pay increases.
Mean total costs for all infants, adjusting for missing data 
using multiple imputation, are found in the online supplemen-
tary table S3. When the missing values were accounted for, faster 
feed increments remain more costly in comparison to slower 
feed increments but at a slightly higher level (£378 more) per 
infant, reflecting the high level of uncertainty in the difference in 
costs, especially with regard to the healthcare resource use after 
discharge estimated by the multiple imputation.
DIsCussIOn
The results of the economic evaluation suggest that for very 
preterm or VLBW infants, daily increments in milk volumes at 
a faster rate (30 mL/kg/day) are per infant more costly and less 
effective in comparison to a slower rate (18 mL/kg/day).
In terms of initial hospital and postdischarge costs between 
the two feeding increments evaluated, a faster increment (30 
mL/kg/day) was shown to be slightly more costly, on average, 
compared with feeding with a slower increment (18 mL/kg/day) 
at 2 years corrected age. The average cost per infant for faster 
increments was £109 917 compared with £109 650 for slower 
increments. However, in terms of the clinical outcomes, faster 
feeds were less effective than slower feeds (18 mL/kg/day) in 
achieving the principal outcome of survival without moderate 
or severe neurodevelopmental disability at 24 months corrected 
age. Fewer infants in the faster increments arm achieved the 
primary clinical outcome (n=802) compared with the slower 
increment arm (n=848).
When the uncertainty around all the estimates is incorporated 
into the analysis, the results suggest that the faster feeding incre-
ment is dominated by the slower feeding increment, as it is on 
average more costly and less effective than the slower increment. 
The cost- effectiveness plane (figure 1) which incorporates the 
uncertainty around each point estimate in the results shows that 
relative to the comparator, faster feeding increments are likely 
to be less cost effective than slower feeding increments (with 
the scatter plot being predominantly to the left of the origin in 
figure 1). The CEAC also shows the low probability of the inter-
vention being cost- effective, which clearly decreases as the will-
ingness to pay increases. Thus, in summary, for very preterm or 
VLBW infants, a faster rate of daily increments in milk volumes 
(30 mL/kg/day) is probably more costly, on average, at 2 years 
corrected age and clearly less effective, with fewer infants 
achieving the principal outcome of survival without moderate to 
severe neurodevelopmental disability. This result is supported by 
the data presented in the cost- effectiveness plane for which the 
majority of the points are in the NW or SW quadrants.
One of the key principles of health economic analysis is to 
maximise the health benefits from, and ensure the most efficient 
allocation of, scarce resources. It is plausible to incur analyses 
that suggest a potentially small decrement in the health outcome 
is acceptable on cost- effectiveness grounds if the potential cost 
saving is great enough to more than offset the loss in health 
outcome and if the saved resources can be used to better effect 
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elsewhere. However, this interpretation does not apply in the 
current analysis due to uncertainty in a number of areas. First, 
regarding costs, the PSA and, in particular, the cost- effectiveness 
plane suggests that faster feeds could be either more or less costly, 
compared with slower feeds. Second, with respect to the clin-
ical effectiveness, the PSA represented in the cost effectiveness 
plane (figure 1) indicates a potential risk for harm associated 
with the faster feeding increment relative to the slower feeding 
increment based on the distribution of the data at 24 months. 
All data points are presented in either the NW (more costly, less 
effective) or SW (less costly, less effective) quadrants. Finally, 
impaired development at 2 years is a serious outcome associated 
with life- long consequences and increased costs across a number 
of sectors including education, healthcare and social care.2
There are also broader societal consequences that could result 
from the clinical outcome, namely productivity loss, stemming 
from both time off work and the lost earnings of parents of chil-
dren with disabilities.1 19 The trial did not collect resource and 
outcome data beyond 2 years.
It is noteworthy that while the costs of initial hospital care 
were lower in those allocated faster increments compared with 
those allocated slower increments, in the specific period from 
initial discharge up to 2 years corrected age, the costs incurred 
by those allocated faster increments were greater overall, per 
infant, compared with those allocated to slower increments, 
potentially revealing problems as the infants mature.
In summary, based on neurodevelopmental outcomes at 2 
years, and given the uncertainty in both the cost and clinical 
effectiveness, the faster feeding increment (rate 30 mL/kg/
day) that was tested in the trial cannot be advocated on cost- 
effectiveness grounds.
strengths and limitations of the study
Strengths of the economic evaluation include that it is the 
first, conducted alongside a randomised controlled trial (RCT) 
comparing enteral feeding practices in infants. SIFT is the largest 
study of any infant feeding intervention ever undertaken in the 
neonatal age group and thus there is broad applicability of this 
economic evaluation, for both policy and practice. The resource 
use and outcome data were prospectively collected at different 
points in the trial. Unit costs were obtained from standard and 
recognised sources. The cost effectiveness results also bene-
fitted from the robustness of the main analyses and stochastic 
analyses.20
A previous clinical systematic review21 identified only four 
RCTs comparing enteral feed volumes in very preterm and VLBW 
infants. All reviewed studies had a very short follow- up period (2 
weeks)22 or no follow- up at all.23 24 Furthermore, none of these 
studies included economic evaluations; thus, conclusions could 
not be made regarding the most cost- effective feeding strategy.
A limitation of this study is that the follow- up period was 
only 2 years. A longer follow- up would have provided greater 
scope for observation of the economic consequences of enteral 
feeding strategies. In particular, the costs and consequences of 
the disabilities/impairments present and the degree of differ-
entiation in health service use between the two feeding groups 
would have been informative. Recall bias is another potential 
limitation as follow- up data were reliant on parent recall over a 
24- month period.
Our analyses required some pragmatic assumptions regarding 
proportions of milk volumes and antibiotic usage during infants’ 
initial hospital stay due to excessive staff burden in data collec-
tion. Nonetheless, our assumptions are supported by existing 
literature and guidelines, and the relatively low cost impact is 
unlikely to have any significant impact on the results.
A further potential limitation of this study is the confusion that 
might arise given that the reported clinical results20 showed faster 
feeds were not statistically significantly different from slower 
feeds for the primary outcome of survival without moderate 
or severe disability at 24 months (corrected for prematurity),20 
whereas the health economics analysis suggests that faster feeding 
increments cannot be supported on cost- effectiveness grounds 
as a result of uncertainty in both the costs and outcomes. This 
contrasting interpretation of the results relates to a requirement 
in the recommendations for health economic analysis14 to esti-
mate and quantify the uncertainty around the clinical endpoints 
using PSA.25 This recommended and widely endorsed approach 
to conducting robust economic analysis is recognised as poten-
tially challenging and has been widely debated and explained 
elsewhere.25 26
COnClusIOn
Based on the results of this within- trial economic evaluation, 
increasing milk feed volumes at the faster rate (30 mL/kg/day) in 
very preterm or VLBW infants is not a cost- effective strategy and 
cannot be recommended.
This work highlights an ongoing debate and also reveals the 
impact of the difference in paradigms between the statistical 
approach and economics approach to analysis.25 27
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